Goldman Sachs
BNTX icon

Goldman Sachs’s BioNTech BNTX Stock Holding History

Goldman Sachs’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.9M Buy
589,903
+493,074
+509% +$46.4M ﹤0.01% 1721
2026
Q1 		$8.61M Sell
96,829
-11,417
-11% -$1.17M ﹤0.01% 3191
2025
Q4 		$10.3M Sell
108,246
-38,338
-26% -$3.86M ﹤0.01% 3067
2025
Q3 		$14.5M Sell
146,584
-37,528
-20% -$4.01M ﹤0.01% 2593
2025
Q2 		$19.6M Sell
184,112
-86,099
-32% -$8.7M ﹤0.01% 2152
2025
Q1 		$24.6M Buy
270,211
+69,741
+35% +$7.81M ﹤0.01% 1828
2024
Q4 		$22.8M Buy
200,470
+170,126
+561% +$19.4M ﹤0.01% 2003
2024
Q3 		$3.6M Sell
30,344
-101,277
-77% -$9.31M ﹤0.01% 3645
2024
Q2 		$10.6M Sell
131,621
-30,461
-19% -$2.78M ﹤0.01% 2452
2024
Q1 		$15M Sell
162,082
-20,796
-11% -$1.99M ﹤0.01% 2095
2023
Q4 		$19.3M Buy
182,878
+42,177
+30% +$4.25M ﹤0.01% 1932
2023
Q3 		$15.3M Sell
140,701
-67,030
-32% -$7.41M ﹤0.01% 2020
2023
Q2 		$22.4M Sell
207,731
-98,092
-32% -$11M ﹤0.01% 1750
2023
Q1 		$38.1M Buy
305,823
+149,721
+96% +$20.6M 0.01% 1259
2022
Q4 		$23.4M Sell
156,102
-31,699
-17% -$4.88M 0.01% 1800
2022
Q3 		$25.3M Sell
187,801
-32,097
-15% -$4.91M 0.01% 1662
2022
Q2 		$32.8M Sell
219,898
-120,879
-35% -$18.5M 0.01% 1471
2022
Q1 		$58.1M Buy
340,777
+12,284
+4% +$2.06M 0.01% 1155
2021
Q4 		$84.7M Buy
328,493
+95,679
+41% +$26.2M 0.02% 910
2021
Q3 		$63.6M Sell
232,814
-76,722
-25% -$24.4M 0.01% 1081
2021
Q2 		$69.3M Buy
309,536
+251,276
+431% +$47.4M 0.02% 1003
2021
Q1 		$6.36M Buy
58,260
+20,811
+56% +$2.21M ﹤0.01% 2926
2020
Q4 		$3.05M Buy
37,449
+26,685
+248% +$2.62M ﹤0.01% 3407
2020
Q3 		$745K Sell
10,764
-137,285
-93% -$9.85M ﹤0.01% 4268
2020
Q2 		$9.88M Buy
+148,049
New +$7.39M ﹤0.01% 2284

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
GP
GSK plc London $602M AUM

Goldman Sachs's BNTX Position: Q2 2026 in Review

Goldman Sachs increased its BioNTech (BNTX) stake by 509% in Q2 2026, buying an estimated $46.4M and bringing the position to 589,903 shares worth $54.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1721.

Goldman Sachs first reported a position in BNTX in Q2 2020 and has held it in 25 quarters since. The position peaked at $84.7M in Q4 2021. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • Goldman Sachs held 589,903 shares of BioNTech worth $54.9M as of Q2 2026.
  • Goldman Sachs bought 493,074 BioNTech shares in Q2 2026, an estimated $46.4M.
  • BioNTech made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1721 holding.
  • Goldman Sachs first reported a position in BioNTech in Q2 2020 and has held it in 25 quarters since.
  • Goldman Sachs's BioNTech position peaked at $84.7M in Q4 2021.
  • 282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.